|Bid||38.02 x 100|
|Ask||50.45 x 100|
|Day's Range||49.52 - 50.40|
|52 Week Range||37.26 - 65.51|
|PE Ratio (TTM)||366.57|
|Earnings Date||Feb 26, 2018 - Mar 2, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||57.08|
As we discussed earlier, Ionis Pharmaceuticals (IONS) is one of the leading biopharmaceutical companies focused on discovering, developing, and commercializing RNA-targeted (ribonucleic acid) therapies. Ionis has created a drug discovery platform and developed many drugs for the treatment of various life-threatening diseases through this broadly applicable platform. Ionis’s revenue sources include its commercial revenue, including its Spinraza royalties and licensing and royalty revenues, and its research and development revenue under its collaborative agreements.
Short interest is moderate for IONS with between 5 and 10% of shares outstanding currently on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Over the last month, growth of ETFs holding IONS is favorable, with net inflows of $3.23 billion.
CARLSBAD, Calif., Jan. 8, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration (FDA). Inotersen is an investigational drug for the treatment of patients with hereditary TTR amyloidosis (hATTR). Priority Review is granted by the FDA to drugs with the potential to address a serious condition and, if approved, would provide a significant improvement in safety or effectiveness of the treatment, prevention, or diagnosis of a serious condition.
CAMBRIDGE, Mass., Jan. 05, 2018-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Ionis Pharmaceuticals, Inc. Here are 5 ETFs with the largest exposure to IONS-US. Comparing the performance and risk of Ionis Pharmaceuticals, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker ... Read more (Read more...)
Categories: Yahoo FinanceGet free summary analysis Ionis Pharmaceuticals, Inc. reports financial results for the quarter ended September 30, 2017. We analyze the earnings along side the following peers of Ionis Pharmaceuticals, Inc. – Alnylam Pharmaceuticals, Inc, Achieve Life Sciences, Inc., Lexicon Pharmaceuticals, Inc., Sangamo Therapeutics, Inc., Pfizer Inc., Regulus Therapeutics Inc. and Astrazeneca PLC Sponsored ADR (ALNY-US, ... Read more (Read more...)
CARLSBAD, Calif., Dec. 21, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) today announced that it has earned a $5 million milestone payment associated with initiation and enrollment in a newly initiated Phase 1 clinical study of IONIS-JBI1-2.5Rx, an orally delivered antisense drug designed to treat patients with a gastrointestinal (GI) immune disorder by reducing the production of an undisclosed target locally in the GI tract. Janssen Biotech, Inc. (Janssen), which is responsible for global development, regulatory and commercialization activities, is conducting the Phase 1 study. "This study represents an important milestone for us and our antisense technology because IONIS-JBI1-2.5Rx is our first orally delivered antisense drug for the treatment of GI disorders to advance into the clinic.
A one-time gene therapy for an inherited retinal disease gained FDA approval this week while Exelixis's (EXEL) Cabometyx can now be used in treatment-naive advanced renal cell carcinoma patients.
Biogen and Ionis Pharmaceuticals, Inc. announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal muscular atrophy .
Huntington's disease (HD) has received clearance under the Hart-Scott-Rodino Antitrust Improvements Act. Based on Roche's decision to license the drug and this approval, Ionis has earned a $45 million license fee from Roche. Roche is now responsible for all IONIS-HTTRx development, regulatory and commercialization activities and costs.
CARLSBAD, Calif., Dec. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 36th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 7:30 a.m. PT in San Francisco, CA. Ionis is the leading company in RNA-targeted drug discovery and development focused on developing drugs for patients who have the highest unmet medical needs, such as those patients with severe and rare diseases. Using its proprietary antisense technology, Ionis has created a large pipeline of first-in-class or best-in-class drugs, with over three dozen drugs in development.
Biogen and Ionis sank after AveXis said it would start trials for a new spinal muscular atrophy treatment.
CAMBRIDGE, Mass., Dec. 14, 2017-- Akcea Therapeutics, Inc., an affiliate of Ionis Pharmaceuticals, Inc., focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases ...
Scientists have for the first time fixed a protein defect that causes Huntington's disease by injecting a drug from Ionis Pharmaceuticals into the spine, offering new hope for patients with the devastating genetic disease. The success in the early-stage clinical trial has prompted Roche to exercise its option to license the product, called IONIS-HTT(Rx), at a cost of $45 million. Lead researcher Sarah Tabrizi, professor of clinical neurology at University College London, said the ability of the drug to tackle the underlying cause of Huntington's by lowering levels of a toxic protein was "ground-breaking".
CARLSBAD, Calif., Dec. 11, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (IONS) announced today that Roche has exercised its option to license IONIS-HTTRx following the completion of a Phase 1/2a randomized, placebo-controlled, dose escalation study of IONIS-HTTRx in people with Huntington's disease (HD). Roche will now be responsible for all development and commercial activities. IONIS-HTTRx is the first therapy in clinical development designed to target the underlying cause of HD by reducing the production of the toxic mutant huntingtin protein (mHTT).